Publication
Decreased Vascular Endothelial Growth Factor (VEGF) Expression in Focal Segmental Glomeruloesclerosis Lesions of Patients Under Sirolimus
| dc.contributor.author | Viana, H | |
| dc.contributor.author | Carvalho, F | |
| dc.contributor.author | Pinto, JR | |
| dc.contributor.author | Galvão, MJ | |
| dc.contributor.author | Santos, A | |
| dc.contributor.author | Nolasco, F | |
| dc.contributor.author | Ribeiro Santos, J | |
| dc.date.accessioned | 2013-01-04T15:20:55Z | |
| dc.date.available | 2013-01-04T15:20:55Z | |
| dc.date.issued | 2007 | |
| dc.description.abstract | Background: Proteinuria (PT) with SRL appears not only after conversion from a calcineurin inhibitor (CI), but also in de novo patients. The PT may be related to a hemodynamic effect of CI withdrawal or to a direct effect of SRL in glomerulus (GL). Recently an association between PT in SRL patients and FSGS lesions has been described. It is also known that SRL decrease VEGF synthesis and experimental data suggest that VEGF is essential to podocyte survival and differentiation. Aim: To determine if glomerular lesions and PT in SRL patients could be related to altered glomerular VEGF expression. Material and methods: We evaluated glomerular VEGF expression in 10 biopsies: A-allograft kidney in backtable (n=3); B-native normal kidney (n=1); C-native kidney with FSGS lesions (n=2); D-allograft kidney with FSGS lesions from proteinuric patients under SRL after conversion from CI (n=3); E-allograft kidney in proteinuric patient under SRL with a membranous glomerulonephritis (n=1). We employed indirect immunohistochemistry in paraffin-embedded sections using a mouse monoclonal antibody against human VEGF-C1 (Santa Cruz). Results: The controls biopsies (A; B) showed normal global VEGF expression, with strong podocyte staining. The VEGF expression in the group C was similar to the controls, although no FSGS lesions were observed in the stained GL. The group D showed normal VEGF expression in the apparently normal GL, hypertrophied podocytes with reduction of VEGF in anomalous GL, and no staining in slcerotic lesions. We observed a gradual reduction of VEGF expression with progressive dedifferentiation of podocytes. In the group E the VEGF was globally reduced, with some hypertrophied podocytes expressing decreased VEGF. Conclusion: We confirmed the diminished VEGF expression in injured podocytes of SRL patients.This decreased expression may result from a direct effect of SRL and precede the appearance of FSGS lesions and PT. Further studies are needed with greater number of cases and controls, including early biopsies of patients under SRL. | por |
| dc.identifier.citation | Renal Week 2007: American Society of Nephrology, Annual Meeting, 2007, 31 Out. a 5 Nov., San Francisco, Califórnia | por |
| dc.identifier.uri | http://hdl.handle.net/10400.17/910 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | Serviço de Nefrologia do Hospital Curry Cabral | por |
| dc.subject | Factores de Crescimento do Endotélio Vascular | por |
| dc.subject | Glomerulosclerose Segmentar e Focal | por |
| dc.subject | Biópsia | por |
| dc.title | Decreased Vascular Endothelial Growth Factor (VEGF) Expression in Focal Segmental Glomeruloesclerosis Lesions of Patients Under Sirolimus | por |
| dc.type | other | |
| dspace.entity.type | Publication | |
| rcaap.rights | openAccess | por |
| rcaap.type | other | por |